Jeffrey Chung, MD
Neurology · West Hollywood, CANPI 1437106366
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,944 of the $13,661 with a category attached, or 65.5%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 72.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $9,982 and has fallen 98.9% since, to $105 in 2025.
Across 43 payments — averaging $317.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Zimmer Biomet$1K
- Monteris Medical Corporation$1K
- Medtronic$717
- Greenwich Biosciences, Inc.$160
- UCB, Inc.$132
- plus $309 from 6 others
Across 3 payments — averaging $8304.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$25K
What the payments were for
- Consulting fees$8,94465%
- Travel & lodging$2,90621%
- Food & beverage$1,81113%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $9,964 |
| Zimmer Biomet | 8 | $1,207 |
| Monteris Medical Corporation | 8 | $1,172 |
| Medtronic | 6 | $717 |
| Greenwich Biosciences, Inc. | 1 | $160 |
| UCB, Inc. | 2 | $132 |
| Sunovion Pharmaceuticals Inc. | 1 | $107 |
| Eisai Inc. | 1 | $76 |
| Neuropace, Inc. | 3 | $71 |
| Livanova USA, Inc. | 1 | $22 |
| Cleerly, Inc. | 1 | $20 |
| Life Molecular Imaging Ltd | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ROSA$1,033
- Neuroblate$950
- ACTIVA$549
- Epidiolex$160
How this compares
$13,661 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 66 | $100,503 |
| FycompaPerampanel | 22 | $35,505 |
| VimpatLacosamide | 25 | $30,228 |
| Tegretol XrCarbamazepine | 17 | $14,570 |
| ValtocoDiazepam | 12 | $8,185 |
| Lacosamide | 37 | $2,904 |
| Clobazam | 15 | $2,813 |
| Lamotrigine ErLamotrigine | 15 | $2,773 |
| Levetiracetam ErLevetiracetam | 24 | $2,287 |
| Levetiracetam | 11 | $1,171 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $979 |
| Gabapentin | 20 | $416 |
| Lamotrigine | 42 | $324 |
| Carbamazepine ErCarbamazepine | 11 | $308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat | $132 | $130,73191 claims |
| Eisai Inc.Fycompa | $76 | $35,50522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.
Other neurology in West Hollywood
- Regina BerkovichWest Hollywood$3M
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.